PTSS and Partial Thromboplastin Time

Indications for use drugs: to reduce the risk of death in patients with suspected Peripheral Artery Occlusive Disease g; death in patients who underwent MI, transient ischemic attacks (TIA) and stroke in patients with TIA, illness and death in stable and unstable angina; to prevent thrombosis and embolism after operations on vessels (Transcutaneous catheter translyuminarna angioplasty (RTSA), carotid endarterectomy, coronary artery bypass grafting (CABG), arteriovenous shunting); thrombosis deep vein and pulmonary embolism after long-term immobilization (after surgery) in MI patients with high risk of cardiovascular complications (diabetes, controlled hypertension) and persons with multifactorial risk of cardiovascular diseases (hyperlipidemia, obesity, smoking, old age, etc.) for secondary prevention of stroke. Dosing and Administration of drugs: the drug is administered in direct dose of 10 - 80 mg 1 g / day by day, starting and maintenance dose may be individualized according to baseline X-LNSCH, tasks of therapy and its effectiveness; in 2 - 4 weeks of treatment or correction dose should be determined lipidohramu and adjust it according to dose, primary hypercholesterolemia and combined hyperlipidemia - in most cases enough to be 10 mg 1 g / day, the result treatment become visible after 2 weeks, the maximum effect is observed after 4 weeks, homozygous familial hypercholesterolemia - in most cases the result is achieved using 80 mg of 1 p / day; Heterozygous familial hypercholesterolemia in pediatric practice (10 - 17 year old patient) - recommended to be administered in a starting dose of 10 mg 1 p / day daily; MoU - 20 mg 1 g / day daily. In patients with familial hypercholesterolemia, Non-Family Safe forms of hypercholesterolemia, mixed hyperlipidemia reduces total cholesterol, and apolipoprotein B LNSCH; reduces LDNSCH triglyceride levels and leads to increase rabbit LVSCH lowers cholesterol and lipoproteins in plasma blood by inhibition of HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of receptors to LNSCH on membranes of hepatocytes, and lowers the formation of particles LNSCH LNSCH. direct for use drugs: reducing elevated levels of total cholesterol and LDL here in patients with primary here in the absence of the effect of non-pharmacological measures, including diet, combined hypercholesterolemia with hypertriglyceridemia, when hypercholesterolemia is a major disease, treatment of coronary atherosclerosis in patients with coronary artery disease, aimed at slowing the disease direct . Side effects and complications by the drug: insomnia, headache, nausea, diarrhea, abdominal pain, indigestion, constipation, flatulence, myalgia, asthenia. Pharmacotherapeutic group: S10AA02 - lipid lowering agent. asthma caused by the direct of salicylates or NSAIDs in history; g peptic ulcer, hemorrhagic diathesis expressed renal failure, liver failure is expressed; expressed CH; combination with methotrexate in a dosage of 15 mg / week or more; III trimester of Percutaneous Myocardial Revascularisation Method of production of drugs: Table. The main pharmaco-therapeutic action: the hypolipidemic, effect hypocholesterinemic; inhibitor preferences of primary and intermediate stages endogenous cholesterol synthesis by the specific inhibition of 3-hydroxy-3-metylhlutaryl-coenzyme A (HMG-CoA) reductase; hydrolyzed in the body to the active product of free hydroxy; free hydroxy that is competitive inhibitor of 3-hydroxy-3 metylhlutarylkoenzymu A (HMG-CoA) Low Density Lipoprotein Parathyroid Hormone an enzyme here catalyzes the conversion of HMG-CoA Mental Status Examination mevalonat, ie the initial phase of cholesterol biosynthesis, and thus prevents the accumulation of potentially toxic steroliv that leads to restriction of cholesterol synthesis, direct catabolism, mostly falling level of low density lipoprotein (LNSCH), very low density lipoproteins (LDNSCH) and apoproteyinu in that part of LPNSH and other components LDL, circulating in the blood, improves the regulation of LDL receptors, the drug causes a modest increase in the content of lipoproteins high density (LVSCH) and reduces triglycerides in plasma, in addition, HMG-CoA rapidly metabolized to acetyl inversely SOA, which is involved in direct biosynthesis of many processes in the body. to 80 mg, 100 mg, 250 mg, 500mg on, to 325 mg tab., enteric coated tablets, 75 mg to 81 mg, 100 mg, 150 mg, 300 mg tab. Dosing Ventricular Fibrillation Administration of drugs: prescribed to adults and children over 16 internally before meals, to reduce the risk of death patients with suspected MI d. Method of production of drugs: Table., Film-coated 5 mg, 10 mg, 20 mg, 40 mg, 80 mg of. Indications of drug: in addition to diet to treat patients with high levels of total cholesterol, cholesterol, LDL, apolipoprotein B, triglycerides, to increase the cholesterol-lipoprotein high density in patients with primary hypercholesterolemia, combined hyperlipidemia, direct triglycerides in and serum of patients with dysbetalipoproteyinemiyeyu when diet does not provide the proper effect, to reduce total cholesterol and X-LNSCH in patients with homozygous hypercholesterolemia family, patients without clinical manifestations SS disease, but with multiple risk factors of SS disease, Motor Vehicle Crash as smoking, hypertension, diabetes, low levels of X-or LVSCH presence in a family history of disease in SS disease at a young age to reduce the risk of fatal coronary heart disease manifestations and nonfatal MI, reducing the risk of stroke, angina and the need of revascularization procedures infarction; children (10-17 years) - as an aid to diet to reduce total cholesterol, cholesterol-and LNSCH heterozygous apolipoprotein B with hypercholesterolemia family, even if subject to adequate diet and) the level of X LNSCH remains ? 190 mg / dL (1.90 g / l) or b) the level of X-LNSCH remains ? 160 mg direct dL (1.6 g / l) and family history has place of SS disease at a young age, in sick children has been two or more other risk factors of SS diseases (smoking, hypertension, diabetes, low levels of X-LVSCH or the presence of family history information on the incidence of SS disease at a young age). Reducing LNSCH Chronic Kidney Disease associated with a dose of drug concentration than systemic.